Обгрунтування створення трансдермальних форм доставки ліків антигіпертензивної дії
DOI:
https://doi.org/10.15587/2519-4852.2023.286303Ключові слова:
артеріальна гіпертензія, інгібітори АПФ, трансдермальні терапевтичні системи, еналаприл, лізиноприл, каптоприлАнотація
У статті викладено теоретичне обґрунтування вибору активних фармацевтичних інгредієнтів антигіпертензивної дії для створення нових форм доставки – трансдермальних терапевтичних систем.
Мета: проведення моніторингу досліджень застосування інгібіторів ангіотензинперетворюючого ферменту (іАПФ) у розробках трансдермальних препаратів для терапії гіпертонічної хвороби.
Матеріали: електронні ресурси відкритого доступу наукової періодики усього світу: Google Scholar (https://scholar.google.com/); PubMed (https://pubmed.ncbi.nlm.nih.gov/); Sciencedirect (https://www.sciencedirect.com/); Pubchem (https://pubchem.ncbi.nlm.nih.gov/); Національна бібліотека України імені В. І. Вернадського (http://www.nbuv.gov.ua/); Український інститут інтелектуальної власності (Укрпатент) (https://sis.ukrpatent.org/uk/); Промислова власність (https://base.uipv.org/searchBul/); USPTO. The United States Patent and Trademark Office (https://www.uspto.gov/patents/search); European Patent Office (EPO) (https://www.epo.org/).
Методи дослідження: інформаційний пошук, теоретичний аналіз та систематизація даних наукових джерел, логічний аналіз.
Результати: здійснено огляд наукових джерел та проведений аналіз іАПФ як кандидатів для створення трансдермальних форм для лікування артеріальної гіпертензії. Визначені фармакологічні та фізико-хімічні аспекти можливості їх використання для введення крізь шкіру. Встановлено, що пошук та розробка новітніх засобів лікування артеріальної гіпертензії, які б значуще збільшували тривалість і якість життя пацієнтів, є вкрай актуальними. Системи трансдермальної доставки ліків є одним із фармацевтичних продуктів, що розробляються на світовому ринку, а їх використання дозоляє подолати супутні недоліки інших шляхів доставки.
Висновки: огляд вітчизняної та зарубіжної літератури підтвердив актуальність біофармацевтичних досліджень у сфері розробки інноваційних лікарських форм – трансдермальних терапевтичних систем для терапії гіпертонічної хвороби.
Обґрунтовано вибір перспективних антигіпертензивних активних фармацевтчиних інгредієнтів групи іАПФ (еналаприлу малеату, лізиноприлу дигідрату та каптоприлу) з урахуванням їх специфічних фізико-хімічних властивостей, які підходять для проникнення через шкіру.
Ринок трансдермальної доставки лікарських засобів збільшується і є перспектива більш високих темпів зростання цього ринку протягом наступних років
Посилання
- Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C. et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 138 (17), e426–e483. doi: https://doi.org/10.1161/cir.0000000000000597
- Mills, K. T., Stefanescu, A., He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16 (4), 223–237. doi: https://doi.org/10.1038/s41581-019-0244-2
- Hypertension (2022). World Health Organization (WHO). Available at: https://www.who.int/health-topics/hypertension/#tab=tab_1
- Stierman, B., Afful, J., Carroll, M. D., Chen, T. et al. (2021). National Health and Nutrition Examination Survey 2017 – March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. National Center for Health Statistics (U.S.), NHSR No. 158. Available at: https://stacks.cdc.gov/view/cdc/106273
- Marushko, Yu.V., Hyshchak, T.V. (2018). Arterialna hipertenziia u ditei ta pidlitkiv. Zdorov’ia Ukrainy. Pediatriia, 4 (47), 53–58. Available at: https://health-ua.com/multimedia/3/9/2/3/5/1547021303.pdf
- Shlimkevych, I. V., Lembryk, I. S., Tsytsiura, O. O., Alekseieva, Yu. I., Zhyliak, O. V. (2022). Arterial hypertension in children and adolescents: a modern view at the problem (a literature review). Part 1. Zaporozhye Medical Journal, 24 (2), 248–253. doi: https://doi.org/10.14739/2310-1210.2022.2.235489
- Senatorova, H. S., Honchar, M. O., Alenina, I. S. et al.; Senatorova, H. S. (Ed.) (2018). Arterialna hipertenziia u ditei. Kharkiv: PLANETA-PRYNT, 108.
- Vsesvitnii den borotby z arterialnoiu hipertenziieiu. Derzhavna ustanova «Tsentr hromadskoho zdorov’ia Ministerstva okhorony zdorov’ia Ukrainy». Available at: https://www.phc.org.ua/news/vsesvitniy-den-borotbi-z-arterialnoyu-gipertenzieyu
- Kumar, G., Virmani, T., Pathak, K., Alhalmi, A. (2022). A Revolutionary Blueprint for Mitigation of Hypertension via Nanoemulsion. BioMed Research International, 2022, 1–12. doi: https://doi.org/10.1155/2022/4109874
- Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y. et al. (2019). Recent progress in drug delivery. Acta Pharmaceutica Sinica B, 9 (6), 1145–1162. doi: https://doi.org/10.1016/j.apsb.2019.08.003
- Bird, D., Ravindra, N. M. (2020). Transdermal drug delivery and patches – An overview. Medical Devices & Sensors, 3 (6). doi: https://doi.org/10.1002/mds3.10069
- Zhao, Z., Ukidve, A., Kim, J., Mitragotri, S. (2020). Targeting Strategies for Tissue-Specific Drug Delivery. Cell, 181 (1), 151–167. doi: https://doi.org/10.1016/j.cell.2020.02.001
- Lee, H., Song, C., Baik, S., Kim, D., Hyeon, T., Kim, D.-H. (2018). Device-assisted transdermal drug delivery. Advanced Drug Delivery Reviews, 127, 35–45. doi: https://doi.org/10.1016/j.addr.2017.08.009
- Steven, J. M. (2019). Press Release Transdermal Drug Delivery Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts, 2017–2023.
- Ramadon, D., McCrudden, M. T. C., Courtenay, A. J., Donnelly, R. F. (2021). Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Delivery and Translational Research, 12 (4), 758–791. doi: https://doi.org/10.1007/s13346-021-00909-6
- Guo, D., Dou, D., Li, X., Zhang, Q., Bhutto, Z. A., Wang, L. (2017). Ivermection-loaded solid lipid nanoparticles: preparation, characterisation, stability and transdermal behaviour. Artificial Cells, Nanomedicine, and Biotechnology, 46 (2), 255–262. doi: https://doi.org/10.1080/21691401.2017.1307207
- Vargason, A. M., Anselmo, A. C., Mitragotri, S. (2021). The evolution of commercial drug delivery technologies. Nature Biomedical Engineering, 5 (9), 951–967. doi: https://doi.org/10.1038/s41551-021-00698-w
- Facts About Hypertension (2022). Centers for Disease Control and Prevention. Atlanta: Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/bloodpressure/facts.htm
- Vsesvitnii den borotby z arterialnoiu hipertenziieiu (2022). Available at: https://www.oblses.ck.ua/index.php?view=article&catid=41%3A2013-05-13-02-14-47&id=2898%3Avsesvitnii-den-borotby-z-arterialnoiu-hipertenziieiu&format=pdf&option=com_content&Itemid=57
- Khyts, A. (2021). Suchasni mozhlyvosti likuvannia arterialnoi hipertenzii: fokus na ostanni rekomendatsii ISH 2020. Ukrainskyi medychnyi chasopys. Available at: https://www.umj.com.ua/article/208823/suchasni-mozhlivosti-likuvannya-arterialnoyi-gipertenziyi-fokus-na-ostanni-rekomendatsiyi-ish-2020
- Korol, S. V. (2021). Arterialna hipertenziia: ohliad suchasnykh rekomendatsii. Zdorov’ia Ukrainy 21 storichchia, 11-12 (504-505). Available at: https://health-ua.com/multimedia/6/6/2/4/2/1626685365.pdf
- Guideline for the pharmacological treatment of hypertension in adults (2021). Geneva: World Health Organization. Available at: https://apps.who.int/iris/bitstream/handle/10665/344424/9789240033986-eng.pdf
- Kulkarni, S., Graggaber, J. (2022). How to improve compliance to hypertension treatment. European Society of Cardiology, 22 (6). Available at: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-22/how-to-improve-compliance-to-hypertension-treatment
- Mishchenko, L. A., Hulkevych, O. V. (2021). Nekontrolovana arterialna hipertenziia: dodatkovi mozhlyvosti pokrashchennia arterialnoho tysku ta yakosti zhyttia patsiientiv. Zdorov’ia Ukrainy 21 storichchia, 6 (499), 45–47. Available at: https://health-ua.com/multimedia/6/4/7/0/4/1619439395.pdf
- Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D. et al. (2020). 2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 38 (6), 982–1004. doi: https://doi.org/10.1097/hjh.0000000000002453
- Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q. et al. (2018). First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews, 2018 (11). doi: https://doi.org/10.1002/14651858.cd008170.pub3
- Herman, L. L., Padala, S. A., Ahmed, I., Bashir, K. (2022). Angiotensin Converting Enzyme Inhibitors (ACEI). StatPearls. Treasure Island (FL). Available at: https://www.ncbi.nlm.nih.gov/books/NBK431051/
- Goyal, A., Cusick, A. S., Thielemier, B. (2022). ACE Inhibitors. StatPearls. Treasure Island. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430896/
- Fountain, J. H., Lappin, S. L. (2022). Physiology, Renin Angiotensin System. StatPearls. NCBI Bookshelf version. StatPearls Publishing.
- Angiotensin Converting Enzyme (ACE) Inhibitors. Clinical Pharmacology (2021). Elsevier.
- Sirenko, Yu. M., Radchenko, H. D. (2004). Rol inhibitoriv anhiotenzynperetvoriuiuchoho fermentu v suchasnomu likuvanni khvorykh z arterialnoiu hipertenziieiu. Ukraynskyi kardyolohycheskyi zhurnal.
- Emilie, W. (2022). ACE Inhibitors: A Class and Utilization Review. Cardiology ADVISOR. Available at: https://www.thecardiologyadvisor.com/ddi/ace-inhibitors/
- Sirenko, Yu. M. (2006). Rol inhibitoriv anhiotenzynperetvoriuiuchoho fermentu v suchasnomu likuvanni sertsevo-sudynnykh zakhvoriuvan. Ratsionalna farmakoterapiia, 1 (1). Available at: https://rpht.com.ua/ua/archive/2006/1%281%29/article-4/rol-ingibitoriv-angiotenzinperetvoryuyuchogo-fermentu-v-suchasnomu-likuvanni-sercevo-sudinnih-zahvoryuvan#
- Rohman, M. S., Fajar, J. K., Kuncahyo, B. H., Yunita, L., Sidarta, E. P., Saka, P. N. B. et al. (2018). Angiotensin-converting enzyme (ACE) I/D and bradykinin B2 receptor T/C genes polymorphism in patients with ACE inhibitors-related cough. Egyptian Journal of Medical Human Genetics, 19 (4), 307–313. doi: https://doi.org/10.1016/j.ejmhg.2018.05.006
- Rahman, M., Pressel. S., Davis, B. R., Nwachuku, C. et al. (2005). Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine, 165 (8), 936–946. doi: https://doi.org/10.1001/archinte.165.8.936
- Anthony, A. B. (2016). Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial – ALLHAT. American College of Cardiology. Available at: https://www.acc.org/latest-in-cardiology/clinical-trials/2014/02/25/15/55/allhatnbsp8212nbsppresented-at-aha-2009
- Unger, T., Paulis, L., Sica, D. A. (2011). Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. European Heart Journal, 32 (22), 2739–2747. doi: https://doi.org/10.1093/eurheartj/ehr253
- Voronkov, L. H. (2007). Inhibitory APF ta adrenoblokatory u likuvanni khronichnoi sertsevoi nedostatnosti: klinichna rol ta metodolohiia zastosuvannia. Ratsionalna farmakoterapiia, 2 (3). Available at: https://rpht.com.ua/ua/archive/2007/2%283%29
- Choi, I. S., Park, I. B., Lee, K., Ahn, T. H., Kim, J. H., Ahn, Y. et al. (2018). Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge. Journal of Cardiovascular Pharmacology and Therapeutics, 24 (2), 120–129. doi: https://doi.org/10.1177/1074248418795897
- Enalapril: Uses, Interaction, Mechanism of Action (2022). DrugBank: a knowledgebase for drugs, drug actions and drug targets. Available at: https://go.drugbank.com/drugs/DB00584
- Lam, P. H., Packer, M., Fonarow, G. C., Faselis, C., Allman, R. M., Morgan, C. J., Singh, S. N., Pitt, B., Ahmed, A. (2020). Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. The American Journal of Medicine, 133 (2), e25–e31. doi: https://doi.org/10.1016/j.amjmed.2019.06.053
- Еналаприл (Enalaprilum). Kompendium. Likarski preparaty. Available at: https://compendium.com.ua/dec/270895/#
- Olvera, L. E., Parmar, M., Pendela, V. S., Jamie M. Terrell (2022). Lisinopril. StatPearls. Treasure Island, StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482230/
- Soloshenko, O. S., Serhyenko, O. M. (2011). Vibor preparata hruppi ynhybytorov APF: effektyvnost, bezopasnost y dostupnost dlia patsyenta. Ukrainskyi Medychnyi Chasopys. Likariu-praktyku, 1 (81), 60–64. Available at: https://www.umj.com.ua/article/9848/vybor-preparata-gruppy-ingibitorov-apf-effektivnost-bezopasnost-i-dostupnost-dlya-pacienta#list
- Lizynopryl (Lisinopril). Kompendium. Likarski preparaty. Available at: https://compendium.com.ua/uk/akt/76/3045/lisinoprilum/
- Obied, A. H. H., Ahmed, A. A. E. (2021). Evaluation of the clinical outcome of captopril use for hypertensive urgency in Khartoum State's emergency centres. African Journal of Emergency Medicine, 11 (1), 202–206. doi: https://doi.org/10.1016/j.afjem.2020.10.003
- Chekman, I. S., Horchakova, N. O., Kazak, L. I. et al.; Chekman, I. S. (Ed.) (2017). Farmakolohiia. Vinnytsia: Nova Knyha, 784.
- Kaptopryl (Captoprilum). Kompendium. Likarski preparaty. Available at: https://compendium.com.ua/akt/67/3102/captoprilum/#toc-0
- Park, S. (2019). Ideal Target Blood Pressure in Hypertension. Korean Circulation Journal, 49 (11), 1002–1009. doi: https://doi.org/10.4070/kcj.2019.0261
- Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M. et al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39 (33), 3021–3104. doi: https://doi.org/10.1093/eurheartj/ehy339
- Abegaz, T. M., Shehab, A., Gebreyohannes, E. A., Bhagavathula, A. S., Elnour, A. A. (2017). Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore), 96 (4), e5641. doi: https://doi.org/10.1097/md.0000000000005641
- Abbas, H., Hallit, S., Kurdi, M., Karam, R. (2022). Non-adherence to antihypertensive medications in Lebanese adults hospitalized for hypertensive urgency and its cost. BMC Cardiovascular Disorders, 22 (1). doi: https://doi.org/10.1186/s12872-022-02907-z
- Lane, D., Lawson, A., Burns, A., Azizi, M., Burnier, M., Jones, D. J. L. et al. (2022). Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 79 (1), 12–23. doi: https://doi.org/10.1161/hypertensionaha.121.17596
- Tan, F. C. J. H., Oka, P., Dambha-Miller, H., Tan, N. C. (2021). The association between self-efficacy and self-care in essential hypertension: a systematic review. BMC Family Practice, 22 (1). doi: https://doi.org/10.1186/s12875-021-01391-2
- Mali, A. D., Bathe, R., Patil, M. (2015). An updated review on transdermal drug delivery systems. International Journal of Advances in Scientific Research, 1 (6), 244–254. doi: https://doi.org/10.7439/ijasr.v1i6.2243
- Pastore, M. N., Kalia, Y. N., Horstmann, M., Roberts, M. S. (2015). Transdermal patches: history, development and pharmacology. British Journal of Pharmacology, 172 (9), 2179–2209. doi: https://doi.org/10.1111/bph.13059
- Singh, I., Morris, A. (2011). Performance of transdermal therapeutic systems: Effects of biological factors. International Journal of Pharmaceutical Investigation, 1 (1), 4–9. doi: https://doi.org/10.4103/2230-973x.76721
- Jeong, W. Y., Kwon, M., Choi, H. E., Kim, K. S. (2021). Recent advances in transdermal drug delivery systems: a review. Biomaterials Research, 25 (1). doi: https://doi.org/10.1186/s40824-021-00226-6
- Vons, B. V., Chubka, M. B., Hroshovyi, T. A. (2017). Transdermal drug delivery system. Pharmaceutical Review, 2, 106–112. doi: https://doi.org/10.11603/2312-0967.2017.2.7902
- Pavan, K. Y., Saurabh M. (2017). Transdermal patch of an antihypertensive drug: its development and evaluation. World Journal of Pharmaceutical Research, 6 (4), 1355–1374. doi: https://doi.org/10.20959/wjpr20174-8214
- Rastogi, V., Pragya, U. P. (2012). A Brief View on Antihypertensive Drugs Delivery through Transdermal Patches. International Journal of Pharmaceutical Sciences and Research, 3 (7), 1955–1970. Available at: https://www.academia.edu/35565081/
- Al Hanbali, O. A., Khan, H. M. S., Sarfraz, M., Arafat, M., Ijaz, S., Hameed, A. (2019). Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharmaceutica, 69 (2), 197–215. doi: https://doi.org/10.2478/acph-2019-0016
- Sharma, P. K., Panda, A., Pradhan, A., Zhang, J., Thakkar, R., Whang, C.-H. et al. (2017). Solid-State Stability Issues of Drugs in Transdermal Patch Formulations. AAPS PharmSciTech, 19 (1), 27–35. doi: https://doi.org/10.1208/s12249-017-0865-3
- Liu, C., Quan, P., Fang, L. (2016). Effect of drug physicochemical properties on drug release and their relationship with drug skin permeation behaviors in hydroxyl pressure sensitive adhesive. European Journal of Pharmaceutical Sciences, 93, 437–446. doi: https://doi.org/10.1016/j.ejps.2016.08.048
- Chandrashekar, N., Shobha Rani, R. (2008). Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery. Indian Journal of Pharmaceutical Sciences, 70 (1), 94–96. doi: https://doi.org/10.4103/0250-474x.40340
- Kokate, A., Li, X., Jasti, B. (2008). Effect of Drug Lipophilicity and Ionization on Permeability Across the Buccal Mucosa: A Technical Note. AAPS PharmSciTech, 9 (2), 501–504. doi: https://doi.org/10.1208/s12249-008-9071-7
- Rahbari, R., Ichim, I., Bamsey, R., Burridge, J., Guy, O. J., Bolodeoku, J., Graz, M. (2020). Characterisation of Drug Delivery Efficacy Using Microstructure-Assisted Application of a Range of APIs. Pharmaceutics, 12(12), 1213. doi: https://doi.org/10.3390/pharmaceutics12121213
- M Elhaj, B., Hamad Farah, F., Saad Ali, H. (2021). Captopril: An Overview of Discovery, Development, and Post-marketingSurveillance as an Effective Anti-hypertensive Drug. Acta Scientific Pharmaceutical Sciences, 5 (4), 6–9. doi: https://doi.org/10.31080/asps.2021.05.0695
- Regulski, Mil. osz, Regulska, K., Stanisz, B., Murias, M., Gieremek, P., Wzgarda, A., Niz.nik, Bartl. omiej. (2015). Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors. Current Pharmaceutical Design, 21 (13), 1764–1775. doi: https://doi.org/10.2174/1381612820666141112160013
- Patel, R. N. (2016). Applications of Biocatalysis for Pharmaceuticals and Chemicals. Organic Synthesis Using Biocatalysis. Academic Press, 339–411. doi: https://doi.org/10.1016/b978-0-12-411518-7.00011-1
- Panchyshyn, Yu. M. (2012). Praktychni aspekty zastosuvannia inhibitoriv APF u khvorykh iz kardiovaskuliarnoiu patolohiieiu. Ratsionalna farmakoterapiia, 3 (24), 22–29. Available at: https://rpht.com.ua/ua/archive/2012/3%2824%29/pages-22-29/praktichni-aspekti-zastosuvannya-ingibitoriv-apf-u-hvorih-iz-kardiovaskulyarnoyu-patologiieyu
- Piepho, R. W. (2000). Overview of the angiotensin-converting-enzyme inhibitors. American Journal of Health-System Pharmacy, 57 (1), S3–S7. doi: https://doi.org/10.1093/ajhp/57.suppl_1.s3
- Derzhavna Farmakopeia Ukrainy (2015). Kharkiv: Derzhavne pidpryiemstvo «Ukrainskyi naukovyi- farmakopeinyi tsentr yakosti likarskykh zasobiv», 1128.
- European Pharmacopoeia. European Directorate for the Quality of Medicines (2019). Strasbourg, 4370.
- Andújar-Sánchez, M., Cámara-Artigas, A., Jara-Pérez, V. (2004). A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme. Biophysical Chemistry, 111 (2), 183–189. doi: https://doi.org/10.1016/j.bpc.2004.05.011
- Hillaert, S., Van den Bossche, W. (2000). Optimization of capillary electrophoretic separation of several inhibitors of the angiotensin-converting enzyme. Journal of Chromatography A, 895 (1-2), 33–42. doi: https://doi.org/10.1016/s0021-9673(00)00591-4
- Remko, M. (2006). Acidity, Lipophilicity, Solubility, Absorption, and Polar Surface Area of Some ACE Inhibitors. Chemical Papers, 61 (2), 133–141. doi: https://doi.org/10.2478/s11696-007-0010-y
- Spiller, H. A. (2014). Angiotensin Converting Enzyme (ACE) Inhibitors. Encyclopedia of Toxicology, 14–16. doi: https://doi.org/10.1016/b978-0-12-386454-3.00686-2
- Foye, W. O., Lemke, T. L., Williams, D. A. (2008). Foye's principles of medicinal chemistry. Lippincott Williams & Wilkins. Available at: https://www.worldcat.org/title/foyes-principles-of-medicinal-chemistry/oclc/145942325
- Di, L., Kerns, E. H. (2003). Profiling drug-like properties in discovery research. Current Opinion in Chemical Biology, 7 (3), 402–408. doi: https://doi.org/10.1016/s1367-5931(03)00055-3
- Hartmann, T., Schmitt, J. (2004). Lipophilicity – beyond octanol/water: a short comparison of modern technologies. Drug Discovery Today: Technologies, 1 (4), 431–439. doi: https://doi.org/10.1016/j.ddtec.2004.10.006
- Odovic, J., Markovic, B., Trbojevic-Stankovic, J., Vladimirov, S., Karljikovic-Rajic, K. (2013). Evaluation of ACE inhibitors lipophilicity using in silico and chromatographically obtained hydrophobicity parameters. Hemijska Industrija, 67 (2), 209–216. doi: https://doi.org/10.2298/hemind120522078o
- Bruno, C. D., Harmatz, J. S., Duan, S. X., Zhang, Q., Chow, C. R., Greenblatt, D. J. (2021). Effect of lipophilicity on drug distribution and elimination: Influence of obesity. British Journal of Clinical Pharmacology, 87 (8), 3197–3205. doi: https://doi.org/10.1111/bcp.14735
- Remko, M., Swart, M., Bickelhaupt, F. M. (2006). Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorganic & Medicinal Chemistry, 14 (6), 1715–1728. doi: https://doi.org/10.1016/j.bmc.2005.10.020
- Stella, V. J., Borchardt, R. T., Hageman, M. J., Oliyai, R., Maag, H., Tilley, J. W. (Eds.) (2007). Prodrugs: Challenges and Rewards. Biotechnology: Pharmaceutical Aspects. New York: Springer Science, Business Media, 1464. doi: https://doi.org/10.1007/978-0-387-49785-3
- Trbojevic, J., Odovic, J., Trbojevic-Stankovic, J., Stojimirovic, B., Jelic, R. (2017). The Evaluation of Angiotensin-Converting Enzyme Inhibitors in Renal Elimination with Selected Molecular Descriptors. Serbian Journal of Experimental and Clinical Research, 18 (2), 119–123. doi: https://doi.org/10.1515/sjecr-2016-0100
- Barna, O. N. (2015). Mistse Dyrotonu sered inhibitoriv APF: vid farmakokinetyky do farmakoekonomiky. Zdorov’ia Ukrainy. Medychni vydannia. Available at: https://health-ua.com/article/18708-mstce-dirotonu-sered-ngbtorv-apf-vd-farmakoknetiki-do-farmakoekonomki
- Zheng, W., Tian, E., Liu, Z., Zhou, C., Yang, P., Tian, K. et al. (2022). Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Frontiers in Pharmacology, 13. doi: https://doi.org/10.3389/fphar.2022.968104
- Gullick, D. R., Pugh, W. J., Ingram, M. J., Cox, P. A., Moss, G. P. (2010). Formulation and characterization of a captopril ethyl ester drug-in-adhesive-type patch for percutaneous absorption. Drug Development and Industrial Pharmacy, 36 (8), 926–932. doi: https://doi.org/10.3109/03639040903585135
- Duraivel, S., Rajalakshmi, A.N., Debjit B. (2014). Formulation and evaluation of captopril Transdermal Patches. Elixir Pharmacy, 76, 28209–28213.
- Pravin, U., Akshata, K., Pravin, C., Manoj, D., Vishal, D. (2016). Formulation and Evaluation of Captopril Transdermal patches for the treatment of hypertension. Available online at www.scholarsresearchlibrary.com. Scholars Research Library. Der Pharmacia Lettre, 8 (5), 12–16.
- Dhanabal, C. (2019). Formulation and Evaluation of Transdermal Delivery System Comprising Captopril as Antihypertensive Drug. Coimbatore: RVS College of Pharmaceutical Sciences.
- Kerımoğlu, O., Şahbaz, S., Şehırlı, Ö., Ozdemır, Z. N., Şule Çetınel, Dortunç, B., Şener, G. (2015). Pharmacodynamical evaluation of matrix type transdermal therapeutic systems containing captopril. Acta Pol Pharm., 72 (4), 799–806. Available at: https://pubmed.ncbi.nlm.nih.gov/26647638/
- Natrajan, R., Rajendran, N.N., Sabareesh, M., Selvaraj, S. (2011). Formulation and evaluation of transdermal delivery of enalapril maleate. International Journal of Pharmaceutical Research., 3, 73–78. Available at: https://www.researchgate.net/publication/287472077_Formulation_and_evaluation_of_transdermal_delivery_of_enalapril_maleate
- Gavali, P., Gaikwad, A., Radhika, P. R., Sivakumar, T. (2010). Design and development of hydroxypropyl methylcellulose (HPMC) based polymeric film of enalapril maleate. InternationalJournal of PharmTech Research, 2 (1), 274–282. Available at: https://sphinxsai.com/sphinxsaivol_2no.1/pharmtech_vol_2no.1/PharmTech_Vol_2No.1PDF/PT%20=44%20(274-282).pdf
- Aqil, M., Bhavna, Chowdhary, I., Sultana, Y., Talegaonkar, S., Ahmad, F. J., Ali, M. M. (2008). Transdermal Therapeutic System of Enalapril Maleate Using Piperidine as Penetration Enhancer. Current Drug Delivery, 5 (2), 148–152. doi: https://doi.org/10.2174/156720108783954860
- Pramod, K. P., Ramesh, K., Rashmi, M. B., Rajarajan, S. (2019). Formulation and Evaluation of Transdermal Patches of an Antihypertensive Drug for Controlled Release. Journal of Emerging Technologies and Innovative Research (JETIR), 6 (6), 444–452. Available at: https://www.jetir.org/papers/JETIR1906210.pdf
- Sabareesh, M., Yanadaiah, J. P., Chandra Sekhar, K. B. (2020). A Novel Vesicular Approach For Transdermal Administration Of Enalapril Maleate Loaded Nanoproniosomal Gel: Formulation, Ex Vivo Evaluation And In Vivo Antihypertensive Study. International Journal of Applied Pharmaceutics, 12 (5), 190–202. doi: https://doi.org/10.22159/ijap.2020v12i5.38463
- Jitendra, B., Pathaka, A. K., Subhash. P. (2010). Development and Optimization of Transdermal System of Lisinopril dehydrate: Employing Permeation Enhancers. Iranian Journal of Pharmaceutical Sciences, 6 (4). Available at: http://www.ijps.ir/article_2166.html
- Rajendra, M., Srinivas, A. (2015). Formulation and Characterization Transdermal Patches for Enhancing the Bio-Availability of Lisinopril Dihydrate. International Journal of Medicine and Nanotechnology, 2 (6), 306–310. Available at: https://www.researchgate.net/publication/296573307
- Aparanjitha, R., Sunitha, R. M., Sarangapani, M. (2020). Formulation And In Vitro Evaluation of Transferosomal Patches for Enhanced Drug Delivery of Lisinopril Dihydrate. Journal of Scientific Research, 64 (3), 105–109. doi: https://doi.org/10.37398/jsr.2020.640318
![Обгрунтування створення трансдермальних форм доставки ліків антигіпертензивної дії](https://journals.uran.ua/public/journals/268/submission_286303_324533_coverImage_uk_UA.png)
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Tatyana Shyteyeva, Elena Bezchasnyuk, Oleg Kryskiv, Vasyl Grynenko
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Наше видання використовує положення про авторські права Creative Commons CC BY для журналів відкритого доступу.